July 01, 2020

SYDNEY, NSW., 1 July, 2020 CooperVision® Australia and New Zealand will launch its new highly-anticipated product, Biofinity® toric multifocal on 7 July.

“This new lens combines the outstanding performance and design of Biofinity® toric and Biofinity® multifocal ,” said Joe Tanner, CooperVision’s Professional Services Manager. “Optometrists now have an easy-to-fit lens, using familiar lens design technologies and the proven Biofinity® silicone hydrogel material. Being able to reliably correct astigmatism means there is no need to compromise visual acuity and we encourage practitioners to use this lens whenever 0.75D or more of astigmatism is present. Furthermore, Biofinity® toric multifocal is fully moulded which confers excellent reproducibility.”


Adding to the extensive Biofinity® range, Biofinity® toric multifocal has over 200,000 unique prescription options1 and is made to order with a normal lead time of 10-15 working days. See lens parameters and other specifications below. For more information, contact your CooperVision® Business Development Manager.


# # #


1 CooperVision Data on file 2019. Based on total number of prescription option combinations manufactured (for sphere, cylinder, axis and ad d including D & N combinations).


About CooperVision

CooperVision, a unit of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as myopia, astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com/.


About CooperCompanies

CooperCompanies (“Cooper”) is a global medical device company public traded on NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.


Media Contact

Joe Tanner, Professional Services Manager, ANZ
Ph: +61 457 800 468